 PALO ALTO, Calif., Jan. 3, 2022 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus HDV and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at the H.C. 